March 24, 2017 — At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions.
Philips exhibited the company's advanced, connected health offerings in the cardiology space at ACC.17, including:
- Azurion – The company’s recently launched, next-generation image-guided therapy platform allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care. Azurion is powered by ConnectOS, a new operating system that provides a seamless integration of real-time information from all relevant technologies in the interventional lab.
- Evolution 3.0 – Philips introduced the X8-2t Live 3D TEE (transesophageal echo) transducer, which allows for new levels of live 3-D imaging with new 3-D TEE features, including a new acoustic design with higher frequencies and bandwidth to provide increased resolution and tissue filling. Fast, easy and confident transthoracic and transesophageal echo allows clinicians to diagnose surgical pathology in real time.
- HeartModel AI – The company’s Anatomical Intelligence Ultrasound (AIUS) application brings advanced automated quantification, 3-D views, robust reproducibility and significant time-savings to echocardiography quantification.
- IntelliSpace Cardiovascular – Provides access to advanced cardiovascular informatics applications, brings multimodality images and clinical tools together in a single workspace for integrated clinical decision support. It seamlessly integrates with the IntelliSpace Portal advanced visualization solution, IntelliSpace ECG (electrocardiogram) data management solution, and the Philips Xper Information Management cath lab workflow solution.
- DreamStation BiPAP autoSV Advanced – Designed to deliver optimal ventilation with minimal intervention for patients with central sleep apnea, complex sleep apnea and periodic breathing. Philips' clinically proven algorithm provides support when needed to help reduce events and normalize ventilation, and works with the patient's breathing pattern to minimize applied pressure, pressure support and machine breaths which can help patients experience comfortable, restful sleep.
Philips also highlighted new iFR (instant wave-Free Ratio) outcome results from over 4,500 patients. The data, which represent the largest randomized coronary physiology outcome studies to date, has the potential to help shape revascularization guidelines.
Read the article “Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation.”
In addition to presenting data around the benefits of iFR technology, Philips hosted "Cardiology Talks," a program of short talks and conversation on key findings, trends and ideas impacting the cardiology specialty today. During the 20-minute sessions, clinicians, scientists and thought leaders shared their experiences and perspectives, discussed innovations, and invited attendees to join in the conversation.
For more information: www.usa.philips.com/healthcare
April 11, 2024 
